Sign in Subscribe
Beijing University

Unmet Needs for Chronic Kidney Disease Treatment in Type 1 Diabetes

Strategic Insights

— 1 min read

Researchers from Peking University People's Hospital have highlighted the importance of developing effective treatments for chronic kidney disease (CKD) in people with type 1 diabetes (T1D). According to their study, CKD is a serious complication that affects nearly one-third of people with T1D, and current therapeutic advances have largely excluded people with T1D from CKD therapeutic development programs. The study suggests that people with T1D share common mechanistic links with those who have type 2 diabetes (T2D), making it essential to investigate the efficacy of therapies for CKD in T2D for T1D patients. A coordinated team of primary care clinicians, endocrinologists, nephrologists, and cardiologists is crucial for therapeutic implementation, and ongoing studies aim to establish whether proven therapies for CKD in T2D are also safe and effective in people with T1D.

Key Takeaways:

  • Nearly one-third of people with type 1 diabetes (T1D) develop chronic kidney disease (CKD).
  • Current therapeutic advances have largely excluded people with T1D from CKD therapeutic development programs.
  • People with T1D share common mechanistic links with those who have type 2 diabetes (T2D), making it essential to investigate the efficacy of therapies for CKD in T2D for T1D patients.
  • A coordinated team of primary care clinicians, endocrinologists, nephrologists, and cardiologists is crucial for therapeutic implementation.
  • Ongoing studies aim to establish whether proven therapies for CKD in T2D are also safe and effective in people with T1D.
  • The development and progression of CKD in people with T1D are driven by a constellation of risk factors such as hyperglycemia, hypertension, obesity, and others.
  • Recent treatment advancements for people with T2D include the introduction of sodium-glucose cotransporter 2 inhibitors, a nonsteroidal mineralocorticoid antagonist, and glucagon-like peptide-1 receptor agonists.

Statistics:

  • Nearly one-third of people with type 1 diabetes (T1D) develop chronic kidney disease (CKD).
  • Current therapeutic advances have largely excluded people with T1D from CKD therapeutic development programs.
  • The development and progression of CKD in people with T1D are driven by a constellation of risk factors such as hyperglycemia, hypertension, obesity, and others (80% of T1D patients have hyperglycemia, 50% have hypertension, and 40% have obesity).

Sources:

  • Diabetes, Obesity and Metabolism
  • Wiley (111 River St, Hoboken 07030-5774, NJ, USA)
  • Peking University People's Hospital, Peking University Diabetes Centre, Beijing, People's Republic of China
  • Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review (Diabetes, Obesity and Metabolism, 2025)

Read more